Biological effects of new corticosterone derivatives

Branceni, D.; Rousseau, Gg.; Jequier, R

doi:10.1016/0039-128x(65)90058-9

“…Apparently, the factor of 7 has been extrapolated from studies in which PRD and DXM were compared regarding other effects, such as their antiinflammatory or thymolytic potential. However, even these studies, summarized in Table 111, do not support this factor of 7 [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. Ratios from 3 up to 240 were found in various systems, mostly studying animals rather than human subjects.…”

Section: Discussionmentioning

confidence: 97%

Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia

Kaspers¹,

Veerman²,

Popp-Snijders³

et al. 1996

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

It is generally assumed that prednisolone (PRD) and dexamethasone (DXM) have equal glucocorticoid activity if PRD is given at sev enfold higher doses. Resuits of clinical studies of childhood acute lymphoblastic leukemia (ALL) suggested that DXM is more potent relative to PRD than assumed. The purpose of this study was to determine the relative antileukemic activ ity of PRD phosphate and DXM phosphate in 133 untreated childhood ALL samples in vitro, using the 3-(4,5-dimethylthiazol-2~y!)-2,5~diphenyltetrazolium-bromide (MTT) assay, There was a marked variation in antileukemic activity of both agents among the patient samples. The median LC50 (drug concentration lethal to 50% of the ALL cells) for PRD phosphate was 3.50 |jlM, for DXM phosphate 0,20 jxM. The individu ally calculated ratios oftheLCSO values for PRD and DXM phosphate showed a large range from 0.7 to > 5 0 0 ; with a median of 16.2. This 16-fold difference could not be explained by differences betw een these glucocorticoids in stability, hy drolysis into unesterified drug, adhesion to the wall o f the microculture plates, or protein bind ing. ALL cells were cross-resistant to PRD and DXM phosphate (correlation coefficient = 0.85, P < 0.000001).W e conclude that the in vitro antileukemic activity o f DXM phosphate is median 16-fold higher than that of PRD phosphate, which contrasts to the generally assumed factor of 7, Based on the higher potency of DXM, and its more favorable pharmacokinetics as reported in the literature, DXM may be pre ferred to PRD as the glucocorticoid in the treatment of ALL.

show abstract

“…Apparently, the factor of 7 has been extrapolated from studies in which PRD and DXM were compared regarding other effects, such as their antiinflammatory or thymolytic potential. However, even these studies, summarized in Table III, do not support this factor of 7 [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41]. Ratios from 3 up to 240 were found in various systems, mostly studying animals rather than human subjects.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia

Kaspers¹,

Veerman²,

Popp‐Snijders³

et al. 1996

Med. Pediatr. Oncol.

View full text Add to dashboard Cite

It is generally assumed that prednisolone (PRD) and dexamethasone (DXM) have equal glucocorticoid activity if PRD is given at sev enfold higher doses. Resuits of clinical studies of childhood acute lymphoblastic leukemia (ALL) suggested that DXM is more potent relative to PRD than assumed. The purpose of this study was to determine the relative antileukemic activ ity of PRD phosphate and DXM phosphate in 133 untreated childhood ALL samples in vitro, using the 3-(4,5-dimethylthiazol-2~y!)-2,5~diphenyltetrazolium-bromide (MTT) assay, There was a marked variation in antileukemic activity of both agents among the patient samples. The median LC50 (drug concentration lethal to 50% of the ALL cells) for PRD phosphate was 3.50 |jlM, for DXM phosphate 0,20 jxM. The individu ally calculated ratios oftheLCSO values for PRD and DXM phosphate showed a large range from 0.7 to > 5 0 0 ; with a median of 16.2. This 16-fold difference could not be explained by differences betw een these glucocorticoids in stability, hy drolysis into unesterified drug, adhesion to the wall o f the microculture plates, or protein bind ing. ALL cells were cross-resistant to PRD and DXM phosphate (correlation coefficient = 0.85, P < 0.000001).W e conclude that the in vitro antileukemic activity o f DXM phosphate is median 16-fold higher than that of PRD phosphate, which contrasts to the generally assumed factor of 7, Based on the higher potency of DXM, and its more favorable pharmacokinetics as reported in the literature, DXM may be pre ferred to PRD as the glucocorticoid in the treatment of ALL.© 1996 wiiey-Uss, inc. From the Departments o f Pediatrics (G.J.L.K., A J.RV., C.H.V.Z., R.P.) and Endocrinology (C.P-S., M .L.), Amsterdam, Dutch Childhood Leu kem ia Study Group (DCLSG) (A.J.P.V., E.R.V.W.), The Hague, and

show abstract

“…Les corticostéroïdes utilisés 2 ont été : la prednisolone, la dexaméthasone et deux dérivés nouveaux de la série corticostérone : la 16a-méthyl ¿J'-corticostérone (R 1178) et la 16a-méthyl 9a-fluoro A '-corticostérone (R 2113) récem ment expérimentés (4). Tous ont été injectés sous forme de suspensions fines dans un dispersif aqueux3.…”

Section: Techniquesunclassified

Efficacité des corticostéroïdes dans le syndrome néphrotique à l’aminonucléoside chez le rat

Branceni¹,

Pottier²,

Chatelet³

et al. 1966

Pharmacology

Self Cite

0

View full text Add to dashboard Cite

Biological effects of new corticosterone derivatives

Cited by 10 publications

References 8 publications

Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia

Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia

Comparison of the antileukemic activity in vitro of dexamethasone and prednisolone in childhood acute lymphoblastic leukemia

Efficacité des corticostéroïdes dans le syndrome néphrotique à l’aminonucléoside chez le rat

Contact Info

Product

Resources

About